PIB TrackerA bioassay needs something to measure against, and IPC has now released one
The Indian Pharmacopoeia Commission released a reference substance for Enoxaparin Sodium bioassays at a 160-participant conference in Bengaluru, giving laboratories an authenticated material to judge biological activity against.
What happened
- The Indian Pharmacopoeia Commission, an autonomous institution under the Ministry of Health and Family Welfare, held a two-day National Conference on the quality and safety of biosimilars on 10-11 September 2026.
- The venue was the Centre for Cellular and Molecular Platforms (C-CAMP), Bengaluru, and 160 participants attended from regulatory authorities, industry, academia and research organisations.
- IPC released an Indian Pharmacopoeia Reference Substance (IPRS) for Enoxaparin Sodium for bioassays, which the release says may serve as an authenticated reference material for bioassay testing.
- Enoxaparin Sodium is a low-molecular-weight heparin and anticoagulant used in the prevention and treatment of thromboembolic disorders.
- The conference was run with IDMA, with BIRAC and C-CAMP as Knowledge Partners and KDPMA as Associate Partner, under the Biopharma SHAKTI Vision.
For Prelims
- Indian Pharmacopoeia Commission (IPC): an autonomous institution under the Ministry of Health and Family Welfare; its Secretary-cum-Scientific Director is Dr V. Kalaiselvan.
- Indian Pharmacopoeia Reference Substance (IPRS): an authenticated reference material used in testing; the one released on 11 September 2026 is for Enoxaparin Sodium bioassays.
- Enoxaparin Sodium: a low-molecular-weight heparin and anticoagulant used in the prevention and treatment of thromboembolic disorders.
- Bioassay: the form of testing this IPRS is meant for; the release links it to accurate, consistent and comparable assessment of a drug's biological activity.
- The conference: two days, 10-11 September 2026, at C-CAMP, Bengaluru, with 160 participants; the subject was the quality and safety of biosimilars.
- Biopharma SHAKTI Vision: the Government framing the conference sits under, stated as innovation, self-reliance, quality and global competitiveness; no outlay or launch date is given in the release.
- Partners: organised with IDMA; Knowledge Partners BIRAC and C-CAMP; Associate Partner KDPMA; SLA-Karnataka and NIB spoke at the inaugural session.
- Subjects covered: pharmacopoeial standards, critical quality attributes, analytical characterisation, comparability assessment, immunogenicity and pharmacovigilance; technical sessions drew WHO and USP experts.
For UPSC: Use this where an answer needs a concrete instance of quality infrastructure rather than a claim about it: regulating a biological depends on having a physical substance to measure a batch against, and that substance is itself something a country either makes or obtains from elsewhere. It fits questions on pharmaceutical standard-setting and regulation, on biotechnology as an industrial sector, and on self-reliance argued at the level of laboratory inputs rather than finished goods.
What it is NOT: The release does not define 'biosimilar', does not say what legal force the Indian Pharmacopoeia or its reference substances carry, and names no Act, rule or regulator that requires their use — its verb is that the IPRS 'may serve' as a reference material. It gives no potency unit, batch, price, quantity or availability date for the substance, no count of IPRS already issued, and no statement that any such standard was previously imported or unavailable in India.
For Mains
Syllabus: GS3.13 · GS2.9 · Linkage L2
Anchor
Self-reliance in pharmaceuticals is usually argued at the level of the finished drug or the active ingredient. The release of an Indian reference substance for Enoxaparin Sodium bioassays moves the argument a layer down, to the authenticated material a laboratory has to hold before it can certify anything at all.
Substantiation (data)
The conference ran two days, 10 and 11 September 2026, at C-CAMP Bengaluru, with 160 participants from regulatory authorities, industry, academia and research organisations, organised by IPC with IDMA, with BIRAC and C-CAMP as Knowledge Partners and KDPMA as Associate Partner. One reference substance was released: the IPRS for Enoxaparin Sodium for bioassays.
Exemplification
Enoxaparin Sodium shows what the standard is for. The release describes it as a low-molecular-weight heparin and anticoagulant used against thromboembolic disorders, and says the IPRS supports accurate, consistent and comparable assessment of its biological activity — a measurement that has to be reported against something already authenticated.
Problematisation
The release stops short of a claim. It says the IPRS may serve as an authenticated reference material, not that it must be used; it names no rule, Act or regulator that makes the Indian Pharmacopoeia binding, and gives no potency unit, batch, price or availability date. An artefact has been announced, not a requirement.
Counterpoint
Against the reading that a two-day conference produced nothing, this one produced a material object with a defined use. Against the reading that the object settles the matter, nothing in the release establishes that Indian laboratories previously lacked such a standard, or how many biosimilars and heparins still have none.
Conclusion
Regulatory capacity is usually counted in approvals and inspections. A pharmacopoeial reference substance is a quieter measure of the same capacity: the ability of the state to say what a correct result looks like. India has issued one more of them, and the release is careful not to say what follows from it.
Deploys into: IT, biotechnology and IPR + statutory and regulatory bodies (GS3.13, GS2.9) · pharmacopoeial standard-setting, biosimilar quality regulation, and self-reliance at the level of laboratory reference materials.
Ministry of Health and Family Welfare · 2026-09-11 · PRID 2309187 · PIB source ↗